Characteristics of patients with TEL-AML1-positive acute lymphoblastic leukemia with single or multiple fusions

Pediatric Blood and Cancer

Volumn 48, Issue 5, 2007, Pages 510-514

  Al Sweedan, Suleimman A ^a   Neglia, Joseph P ^a,c   Steiner, Marie E ^a   Bostrom, Bruce C ^b   Casey, Timothy ^b   Hirsch, Betsy A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

ALL; Molecular genetics; Outcome research

Indexed keywords

CD33 ANTIGEN; MICROSOMAL AMINOPEPTIDASE; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FREQUENCY; GENE FUSION; GENE TRANSLOCATION; HUMAN; INFANT; MALE; MARKER GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE RISK; SCHOOL CHILD; SEX DIFFERENCE;

ANTIGENS, CD; ANTIGENS, CD13; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, 21-22 AND Y; CHROMOSOMES, HUMAN, 6-12 AND X; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC;

EID: 33947709535     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20911     Document Type: Article

References (48)

1. Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993;81:2237-2251.
2. Romana SP, Le CM, Berger R. t (12; 21): A new recurrent translocation in acute lymphoblastic leukemia. Genes Chromosomes Cancer 1994;9:186-191.
3. Romana SP, Mauchauffc M, Lc CM, et al. The t(12;21) of acute lymphoblastic leukemia results in a TEL-AML1 gene fusion. Blood 1995;85:3662-3670.
4. Gunji H, Waga K, Nakamura F, et al. TEL/AML1 shows dominant-negative effects over TEL as well as AML1. Biochem Biophys Res Commun 2004;322:623-630.
5. Poirel H, Oury C, Carron C, et al. The TEL gene products: Nuclear phosphoproteins with DNA binding properties. Oncogene 1997; 14:349-357.
6. Lopez RG, Carron C, Oury C, et al. TEL is a sequence-specific transcriptional repressor. J Biol Chem 1999;274:30132-30138.
7. Rompaey LV, Potter M, Adams C, et al. Tel induces a G1 arrest and suppresses Ras-induced transformation. Oncogene 2000;19:5244-5250.
8. Fenrick R, Wang L, Nip J, et al. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Mol Cell Biol 2000;20:5828-5839.
9. Wang S, Wang Q, Crute BE, et al. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 1993;13:3324-3339.
10. Tsang KS, Li CK, Chik KW, et al. TEL/AML1 rearrangement and the prognostic significance in childhood acute lymphoblastic leukemia in Hong Kong. Am J Hematol 2001;68:91-98.
11. Kitabayashi I, Yokoyama A, Shimizu K, et al. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 1998;17:2994-3004.
12. Gu X, Shin BH, Akbarali Y, et al. Tel-2 is a novel transcriptional repressor related to the Ets factor Tel/ETV-6. J Biol Chem 2001; 276:9421-9436.
13. Hiebert SW, Sun W, Davis JN, et al. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996;16:1349-1355.
14. Fears S, Gavin M, Zhang DE, et al. Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter. Proc Natl Acad Sci USA 1997;94:1949-1954.
15. Fenrick R, Amann JM, Lutterbach B, et al. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. MoI Cell Biol 1999;19:6566-6574.
16. Guidez F, Petrie K, Ford AM, et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 2000;96: 2557-2561.
17. Rubnitz JE, Pui CH, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999;13:6-13.
18. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-1989.
19. Zuna J, Hrusak O, Kalinova M, et al. TEL/AML1 positivity in childhood ALL: Average or better prognosis? Czech Paediatric Haematology Working Group. Leukemia 1999;13:22-24.
20. Loh ML, Silverman LB, Young ML, et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998;92:4792-4797.
21. Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999; 13:19-21.
22. Zana J, Hrusak O, Kalinova M, et al. Significantly lower relapse rate for TEL/AML1-positive ALL. Leukemia 1999;13:1633.
23. Konrad M, Metzler M, Panzer S, et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: Evidence for the persistence of a preleukemic clone. Blood 2003;101:3635-3640.
24. Maloney K, McGavran L, Murphy J, et al. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia 1999;13:1708-1712.
25. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996;88:4252-4258.
26. Harbott J, Viehmann S, Borkhardt A, et al. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997;90:4933-4937.
27. Seeger K, Adams HP, Buchwald D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 1998;91: 1716-1722.
28. Seeger K, Buchwald D, Taube T, et al. TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Berlin-Frankfurt- Munster Study Group. Leukemia 1999;13: 1469-1470.
29. Attarbaschi A, Mann G, Konig M, et al. Austrian Berlin-Frankfurt-Munster cooperative study group. Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: An interphase FISH analysis. Leukemia 2004;18:1611-1616.
30. Raynaud SD, Dastugue N, Zoccola D, et al. Cytogenetic abnormalities associated with the t(12;21): A collaborative study of 169 children with t(12;21)-positive acute lymphoblastic leukemia. Leukemia 1999;13:1325-1330.
31. Loncarevic IF, Roitzheim B, Ritterbach J, et al. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. Genes Chromosomes Cancer 1999;24:272-277.
32. Aguiar RC, Sohal J, van Rhee F, et al. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996;95:673-677.
33. Ma SK, Wan TS, Cheuk AT, et al. Characterization of additional genetic events in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion: A molecular cytogenetics study. Leukemia 2001;15:1442-1447.
34. Niini T, Kanerva J, Vettenranta K, et al. AML1 gene amplification: A novel finding in childhood acute lymphoblastic leukemia. Haematologica 2000;85:362-366.
35. Fears S, Vignon C, Bohlander SK, et al. Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 1996;17:127-135.
36. Kobayashi H, Satake N, Maseki N, et al. The der(21)t(12;21) chromosome is always formed in a 12;21 translocation associated with childhood acute lymphoblastic leukaemia. Br J Haematol 1996;94:105-111.
37. Andreasson P, Johansson B, Strömbeck B, et al. Childhood acute lymphoblastic leukaemia with ider(21)(q10)t(12;21)(p12;q22): A new recurrent abnormality showing ETV6/CBFA2 fusion. Br J Haematol 1997;98:216-218.
38. Eguchi-Ishimae M, Eguchi M, Tanaka K, et al. Fluorescence in situ hybridization analysis of 12;21 translocation in Japanese childhood acute lymphoblastic leukemia. Jpn J Cancer Res 1998;89:783-788.
39. Douet-Guilbert N, Morel F, Le Bris MJ, et al. A fluorescence in situ hybridization study of TEL-AML1 fusion gene in B-cell acute lymphoblastic leukemia (1984-2001). Cancer Genet Cytogenet 2003;144:143-147.
40. Martinez-Ramirez A, Urioste M, Contra T, et al. Fluorescence in situ hybridization study of TEL/AML1 fusion and other abnormalities involving TEL and AML1 genes. Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia. Haematologica 2001;86:1245-1253.
41. Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999; 13:19-21.
42. Pui C-H, Evans WE. Acute lymphoblastic leukemia. New Engl J Med 1998;339:605-614.
43. Tsang KS, Li CK, Chik KW, et al. TEL/AML1 rearrangement and the prognostic significance in childhood acute lymphoblastic leukemia in Hong Kong. Am J Hematol 2001;68:91-98.
44. Fink PM, Roller U, Mayer H, et al. Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. The Austrian Pediatric Oncology Group. Med Pediatr Oncol 1993;21:340-346.
45. Wiersma SR, Ortega J, Sobel E, et al. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991;324:800-808.
46. Plensa E, Ribera JM, Oriol A, et al. Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia. Med Clin (Barc) 2005;125:241-246.
47. Kalina T, Vaskova M, Mejstrikova E, et al. Myeloid antigens in childhood lymphoblastic leukemia: Clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer 2005;5:38.
48. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-1731.